News

June St. Jude Medical Inc. announced preliminary results from the EnligHTN III study, which found the company’s second-generation EnligHTN renal denervation system provided safe and effective...

Journal of Endovascular Therapy Hypertension Renal Denervation Therapy

Patients with hypertension after renal artery stenting who do not respond to drug treatment may have another option. 

Power Plate Whole Body Vibration Blood Pressure Florida State University

Six independent studies published within the past 10 years have shown a link between whole body vibration and lowered blood pressure.

May 14, 2014 — The Department of Health and Human Services (HHS) announced that new preliminary data show an overall 9 percent decrease in hospital-acquired conditions nationally during 2011 and...

It is impossible to escape the reality that as the use of mobile electronic devices increases amongst consumers, a proportionate increase in the use of such devices in the medical sales and...

Cardiosonic Inc CE mark TIVUS ablative catheter renal denervation hypertension

Cardiosonic Ltd. announced CE marking of its TIVUS (therapeutic intravascular ultrasound) ablative catheter device.

Medtronic, SYMPLICITY, SYMPLICITY HTN-3 trial, renal denervation, ACC.14

A major disappointment earlier this year was the announcement by Medtronic that its renal denervation system failed to meet its primary endpoint for efficacy in the U.S. SYMPLICITY HTN-3 trial....

CBSET Renal Denervation Hypertension Therapies Symplicity-3 Trial

Scientists at CBSET are reminding thought leaders in renal denervation that there is a seminal experimental and computational template for the more rational, comprehensive preclinical evaluation...

ReCor Medical Paradise System Renal Denervation RDN Therapy Hypertension

ReCor Medical advanced its Paradise System for renal denervation (RDN) for treatment resistant ...

SHEA Infection Control General Cardiology CT Systems White Coats

The Society for Healthcare Epidemiology of America (SHEA), an infection control organization, issued voluntary...

FDA Premarket Approval PMA Clinical Study EP Lab Cath Leads Implantable Devices

The U.S. Food and Drug Administration (FDA) has approved many cardiac implantable electronic device...

hypertension therapies cvrx barostim neo therapy

CVRx Inc. announced findings from a health-economic analysis published in the Journal of Hypertension that indicates Barostim Therapy is a cost-effective treatment option for...

Medtronic, symplicity, renal denervation

Medtronic Inc. announced its U.S. pivotal trial for its Symplicity renal denervation system to treat resistant hypertension, the SYMPLICITY HTN-3 trial, failed to meet its primary efficacy...

medtronic symplicity renal denervation therapy hypertension cath lab trial study

Medtronic Inc. announced that the first patients were randomized in Symplicity HTN-4, which will evaluate the Symplicity ...

medtronic symplicity spyral renal denervation cath lab hypertension treatment G3

Medtronic Inc. announced CE mark in Europe and Therapeutic Goods Administration (TGA) listing in Australia for its flexible 4 French multi-electrode Symplicity Spyral ...

Medtronic, Inc. presented three-year data from SYMPLICITY HTN-2, the first and longest-running randomized, controlled clinical trial of renal denervation, which continue to demonstrate results...

The 2014 Top 10 Health Technology Hazards list raises awareness of the potential dangers associated with the use of medical devices and helps healthcare providers minimize the risk of technology-...

renal stenting

The use of renal stenting in combination with medication-based therapy to treat hypertension showed no improvement in patient outcomes over the use of medications alone in treating hypertension....

Petr Neuzil, M.D., Nemocnice Na Homolce Hospital, Prague, Czech Republic, presented three-month results from the WAVE II study and complete six-month results for the WAVE I (first-in-man) at the...

renal denervation clinical trial study hypertension cath medtronic symplicity

Medtronic Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE), allowing the company to initiate SYMPLICITY HTN-4, the first...